X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (471) 471
Publication (53) 53
Book Review (9) 9
Newspaper Article (5) 5
Book Chapter (3) 3
Newsletter (3) 3
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fulvestrant (395) 395
breast cancer (280) 280
index medicus (266) 266
humans (244) 244
oncology (241) 241
female (226) 226
postmenopausal women (192) 192
endocrine therapy (183) 183
estradiol - analogs & derivatives (176) 176
breast neoplasms - drug therapy (157) 157
double-blind (134) 134
estrogen (124) 124
tamoxifen (121) 121
metastasis (110) 110
cancer (101) 101
breast neoplasms - pathology (98) 98
estradiol - pharmacology (96) 96
receptors, estrogen - metabolism (96) 96
anastrozole (93) 93
care and treatment (90) 90
breast neoplasms - metabolism (81) 81
chemotherapy (77) 77
fulvestrant 500 mg (76) 76
antineoplastic agents, hormonal - therapeutic use (75) 75
animals (70) 70
estradiol - therapeutic use (66) 66
middle aged (64) 64
cancer therapies (63) 63
medicine & public health (62) 62
estrogen-receptor (60) 60
research (60) 60
women (58) 58
1st-line treatment (57) 57
aromatase inhibitors (56) 56
tumors (56) 56
palbociclib (55) 55
analysis (54) 54
therapy (53) 53
health aspects (52) 52
aged (51) 51
letrozole (51) 51
pharmacology & pharmacy (50) 50
estradiol - administration & dosage (48) 48
estrogen antagonists - pharmacology (48) 48
advanced breast cancer (46) 46
drug therapy (46) 46
postmenopause (46) 46
trial (46) 46
antineoplastic agents (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
metastases (45) 45
metastatic breast cancer (45) 45
estrogen receptor (44) 44
randomized-trial (44) 44
treatment outcome (44) 44
epidermal growth factor (43) 43
gene expression (43) 43
patients (43) 43
antimitotic agents (42) 42
clinical trials (42) 42
combination (42) 42
anastrozole 1 mg (40) 40
hormones (40) 40
endocrine resistance (39) 39
endocrinology & metabolism (39) 39
estrogen receptors (39) 39
erbb-2 protein (38) 38
adult (37) 37
cell line, tumor (37) 37
first-line therapy (37) 37
womens health (37) 37
development and progression (36) 36
kinases (36) 36
estradiol - adverse effects (34) 34
expression (34) 34
breast neoplasms - mortality (33) 33
hematology, oncology and palliative medicine (33) 33
phenols (33) 33
disease-free survival (32) 32
estradiol (32) 32
mutation (32) 32
estrogens (31) 31
phase-iii trial (31) 31
receptors, progesterone - metabolism (31) 31
survival (31) 31
article (30) 30
biochemistry & molecular biology (30) 30
cell cycle (30) 30
neoplasms. tumors. oncology. including cancer and carcinogens (30) 30
phase-iii (30) 30
tamoxifen - pharmacology (30) 30
aged, 80 and over (29) 29
neoplasm metastasis (29) 29
resistance (29) 29
aromatase inhibitors - therapeutic use (28) 28
dosage and administration (28) 28
everolimus plus exemestane (28) 28
obstetrics & gynecology (28) 28
prognosis (28) 28
progression-free survival (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 14458 - 7
Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including... 
FDG-PET/CT | SURVIVAL | CELLS | THERAPY | F-18-FDG PET/CT | PATHWAY | GLUCOSE | MULTIDISCIPLINARY SCIENCES | Statistical analysis | Liver | Breast cancer | Metastasis | Multivariate analysis | Drug resistance | Survival | Patients | ErbB-2 protein | Fulvestrant | Metastases | Computed tomography | Medical prognosis | Glycolysis | Positron emission tomography
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 03/2017, Volume 109, Issue 3, p. 1
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, p. 206
Background The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg... 
Therapy | Randomization | Anastrozole | Clinical trials | Endocrine therapy | Breast cancer | Patients | Quality of life | Post-menopause | Fulvestrant | Cancer | Metastases
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, pp. 206 - 215
The phase III randomised FALCON trial ( ) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine... 
Health-related quality of life | FALCON | Anastrozole | Locally advanced or metastatic breast cancer | Fulvestrant | 1ST-LINE TREATMENT | WOMEN | 1ST | THERAPY | ONCOLOGY | ABC 3 | INTERNATIONAL CONSENSUS GUIDELINES | Breast cancer | Postmenopausal women | Metastasis | Hormones | Analysis
Journal Article
Breast Cancer, ISSN 1340-6868, 11/2019, Volume 26, Issue 6, pp. 703 - 711
Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive... 
Clinical benefit rate | Medicine & Public Health | Advanced breast cancer | Surgery | Oncology | Cancer Research | Surgical Oncology | Hormone receptor-positive | Fulvestrant | Meta-analysis | Original
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 06/2019, Volume 19, Issue 3, pp. e452 - e458
Fulvestrant 500 mg and exemestane are widely used agents in first-line therapy for metastatic breast cancer (MBC) of estrogen receptor (ER)-positive (ER )... 
Endocrine therapy | Metastatic breast cancer | Endocrine sensitivity | ER+ HER2− breast cancer | Fulvestrant | breast cancer | HER2 | PLACEBO | ER+ HER2(-) breast cancer | ONCOLOGY | GUIDELINES | ESR1 MUTATIONS | DOUBLE-BLIND | ANASTROZOLE
Journal Article
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A435
Journal Article
Breast Cancer, ISSN 1340-6868, 7/2016, Volume 23, Issue 4, pp. 617 - 623
Journal Article
Journal of Nippon Medical School, ISSN 1345-4676, 06/2019, Volume 86, Issue 3, pp. 165 - 171
Background: Fulvestrant 500 mg has been an option for endocrine therapy for advanced or recurrent breast cancer after prior endocrine treatment since November... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | cohort study | THERAPY | fulvestrant | DOUBLE-BLIND | advanced/relapsed breast cancer | Japanese
Journal Article
Journal Article
Journal Article
Journal Article